G. Demir Et Al. , "Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)," ANTICANCER RESEARCH , vol.19, pp.3517-3520, 1999
Demir, G. Et Al. 1999. Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study). ANTICANCER RESEARCH , vol.19 , 3517-3520.
Demir, G., Ozguroglu, M., Sayhan, N. Ş., Molinas-Mandel, N., Demirelli, F. H., Buyukunal, E., ... Tuzuner, N.(1999). Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study). ANTICANCER RESEARCH , vol.19, 3517-3520.
Demir, G Et Al. "Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)," ANTICANCER RESEARCH , vol.19, 3517-3520, 1999
Demir, G Et Al. "Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)." ANTICANCER RESEARCH , vol.19, pp.3517-3520, 1999
Demir, G. Et Al. (1999) . "Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)." ANTICANCER RESEARCH , vol.19, pp.3517-3520.
@article{article, author={G Demir Et Al. }, title={Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)}, journal={ANTICANCER RESEARCH}, year=1999, pages={3517-3520} }